2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Sunday, November 8, 2015

2:30PM-4:00PM: Abstract Number: 924

Patient and Provider Factors in Optimal Gout Management

Health Services Research I: Digital Health and Patient, Provider Factors in Rheumatic Disease

2:30PM-4:00PM: Abstract Number: 920

Patient Preferences for the Development of a Mobile Health (mHealth) Application (App) for Systemic Lupus Erythematosus (SLE) Patients: A Qualitative Study

Health Services Research I: Digital Health and Patient, Provider Factors in Rheumatic Disease

2:30PM-4:00PM: Abstract Number: 911

Patients with Rheumatoid Arthritis Are at Increased Risk of Both Ischemic and Non-Ischemic Heart Failure

Epidemiology and Public Health I: RA Comorbidities and Mortality

2:30PM-4:00PM: Abstract Number: 923

Perceptions of Infectious Risk of Immunosuppressive Medications Among Treating Physicians

Health Services Research I: Digital Health and Patient, Provider Factors in Rheumatic Disease

2:30PM-4:00PM: Abstract Number: 990

Performance of the Systemic Lupus International Collaborating Clinic Classification Criteria Versus the 1982 and Revised 1997 American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus: A Population-Based Study

Systemic Lupus Erythematosus - Clinical Aspects and Treatment I: Epidemiology and Prognosis

2:30PM-4:00PM: Abstract Number: 934

Platelet-Independent Role of Megakaryocytes in Antibody-Mediated Murine Arthritis

Innate Immunity and Rheumatic Disease

2:30PM-4:00PM: Abstract Number: 921

Poverty Associated with Increase in Damage in SLE over Two-Year Period

Health Services Research I: Digital Health and Patient, Provider Factors in Rheumatic Disease

2:30PM-4:00PM: Abstract Number: 987

Pre-Emptive Renal Transplantation Among End Stage Renal Disease Patients with and without SLE

Systemic Lupus Erythematosus - Clinical Aspects and Treatment I: Epidemiology and Prognosis

2:30PM-4:00PM: Abstract Number: 962

Profiling at the Single-Cell Level Reveals Evidence for Antigen-Driven Oligoclonal Expansion of Citrullinated Vimentin-Specific CD4+ T Cells in Peripheral Blood of Rheumatoid Arthritis (RA) Patients

Rheumatoid Arthritis - Human Etiology and Pathogenesis I

2:30PM-4:00PM: Abstract Number: 941

Relationship Between Colchine Plasma Level and Frequency of Familial Mediterranean Fever Attacks

Miscellaneous Rheumatic and Inflammatory Diseases I

2:30PM-4:00PM: Abstract Number: 959

Results from the Childhood Arthritis and Rheumatology Research Alliance Systemic JIA Consensus Treatment Plans Pilot Study

Pediatric Rheumatology - Clinical and Therapeutic Aspects I: Juvenile Idiopathic Arthritis

2:30PM-4:00PM: Abstract Number: 937

Safety and Efficacy of Canakinumab in Patients with CAPS: Interim Results from the Beta-Confident Registry

Miscellaneous Rheumatic and Inflammatory Diseases I

2:30PM-4:00PM: Abstract Number: 971

Safety and Tolerability of Subcutaneous Sarilumab Compared to Intravenous Tocilizumab in Patients with RA

Rheumatoid Arthritis-Small Molecules, Biologics and Gene Therapy I: Biologics

2:30PM-4:00PM: Abstract Number: 967

Safety, Tolerability, and Pharmacodynamics of ABT-122, a Dual TNF- and IL-17-Targeted Dual Variable Domain (DVD)-IgTM in Subjects with Rheumatoid Arthritis

Rheumatoid Arthritis-Small Molecules, Biologics and Gene Therapy I: Biologics

2:30PM-4:00PM: Abstract Number: 912

Secondary Preventive Pharmacotherapy and Longterm Outcomes Following Acute Coronary Events in Patients with Prevalent Rheumatoid Arthritis

Epidemiology and Public Health I: RA Comorbidities and Mortality

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].